Acelrx pharmaceuticals inc (ACRX)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Sep'10Jun'10
Revenue:
Revenue

386

475

608

941

265

613

377

818

343

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Collaboration agreement

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,562

1,314

1,793

327

13,863

486

181

226

4,825

71

95

-

-

-

0

-

-

-

-

-

-

-

-

-

-

Contract and other

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,804

3,217

1,232

1,403

1,565

1,438

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research grant

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

548

407

940

1,675

166

224

329

-

408

40

-

-

-

Revenue

-

-

-

-

-

-

-

-

-

-

1,487

2,659

3,109

6,435

3,366

4,531

3,025

1,730

15,428

1,924

181

-

4,825

71

-

27,607

548

407

940

-

-

-

-

-

-

-

-

-

-

Operating costs and expenses:
Cost of goods sold

1,511

1,618

2,148

1,810

1,230

1,238

875

749

1,114

962

2,029

3,543

4,125

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cost of goods sold

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,579

2,976

3,599

1,770

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development

1,412

1,063

1,058

1,163

1,377

2,704

3,642

3,278

3,513

3,676

3,913

4,901

6,919

6,334

4,617

6,280

4,171

3,479

5,393

7,310

6,306

7,281

5,244

7,284

4,711

4,318

6,548

6,108

9,318

7,795

6,948

5,394

4,771

4,702

3,947

3,029

1,946

1,515

2,033

Selling, general and administrative

13,311

12,786

10,936

11,329

9,976

7,648

5,188

3,944

3,985

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total operating costs and expenses

16,234

15,467

14,142

14,302

12,583

11,590

9,705

7,971

8,612

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

General and administrative

-

-

-

-

-

-

-

-

-

-

4,406

4,156

4,138

4,078

4,145

3,597

3,777

4,017

2,930

2,735

4,521

4,724

4,650

5,047

3,925

3,306

2,310

2,070

2,191

1,909

1,410

1,776

2,104

1,715

1,866

1,630

1,589

1,090

1,276

Restructuring costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

2

754

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total operating costs and expenses

-

-

-

-

-

-

-

-

-

-

10,348

12,600

15,182

13,573

11,341

12,853

11,547

9,266

8,323

10,047

11,581

12,005

9,894

12,331

8,636

7,624

8,858

8,178

11,509

9,704

8,358

7,170

6,875

6,417

5,813

4,659

3,535

2,605

3,309

Loss from operations

-15,848

-14,992

-13,534

-13,361

-12,318

-10,977

-9,328

-7,153

-8,269

-7,807

-8,861

-9,941

-12,073

-7,138

-7,975

-8,322

-8,522

-7,536

7,105

-8,123

-11,400

-

-5,069

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other expense:
Interest income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

8

-

-

Interest expense

855

831

828

500

376

459

529

586

643

720

919

903

774

701

702

687

680

681

713

777

806

821

816

530

472

313

348

403

454

518

573

598

594

417

377

156

1,359

197

214

Interest income and other (expense) income, net

-65

438

645

456

627

495

312

195

136

725

-465

396

-146

618

-360

241

419

-195

-269

4

2,180

-

6,556

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash interest income (expense) on liability related to future sale of royalties

-843

-962

-986

-996

1,607

1,617

2,913

2,995

2,816

2,786

2,768

2,609

2,558

2,461

2,401

2,324

2,196

2,146

282

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total other expense

-77

569

803

952

-1,356

-1,581

-3,130

-3,386

-3,323

-2,781

-4,152

-3,116

-3,478

-2,544

-3,463

-2,770

-2,457

-3,022

-1,264

-773

1,374

-3,041

5,740

2,215

-618

-3,419

-2,328

-9,273

-1,739

-1,975

183

350

75

-155

21

12

1,682

-799

-14

Net loss before income taxes

-

-

-12,731

-12,409

-

-

-12,458

-10,539

-

-

-13,013

-13,057

-

-

-11,438

-11,092

-

-

-

-

-

-

-

-12,260

-8,541

-

-8,310

-7,771

-10,569

-8,029

-8,192

-6,946

-6,546

-5,793

-5,405

-4,619

-3,535

-2,605

-3,309

Net loss before income taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-10,979

-

5,841

-8,896

-10,026

-

671

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Provision (benefit) for income taxes

-

-

-

3

-

-

-

2

-

-

0

2

-

0

-36

0

2

-12

772

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-15,925

-14,423

-12,731

-12,412

-13,674

-12,558

-12,458

-10,541

-11,592

-9,885

-13,013

-13,059

-15,551

-9,682

-11,402

-11,092

-10,981

-10,546

5,069

-8,896

-10,026

-13,818

671

-10,575

-9,631

17,769

-10,986

-17,447

-12,762

-10,522

-8,582

-7,194

-7,065

-6,373

-5,761

-4,763

-3,204

-3,601

-3,537

Other comprehensive loss:
Unrealized losses on available for sale securities

-

-

-

-

-

-

-

-

-

0

0

2

-5

2

-5

2

5

-3

1

1

4

-

1

-2

-

-

5

0

-2

0

4

-1

-2

-

5

-

-

-

-

Comprehensive loss

-15,925

-14,423

-12,731

-12,412

-13,674

-12,558

-12,458

-10,541

-11,592

-9,885

-13,013

-13,057

-15,556

-9,680

-11,407

-11,090

-10,976

-10,549

5,070

-8,895

-10,022

-13,822

672

-10,577

-9,631

17,766

-10,981

-17,447

-12,764

-10,522

-8,578

-7,195

-7,067

-6,379

-5,755

-4,763

-3,204

-

-

Net loss per share of common stock, basic (in dollars per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.24

-0.24

-0.23

0.11

-0.20

-0.23

-0.33

0.02

-0.24

-0.22

-

-0.26

-0.47

-

-

-

-

-

-

-

-

-

-

-

Net loss per share of common stock, diluted (in dollars per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.24

-0.25

-0.24

0.11

-0.20

-0.27

-0.26

-0.13

-0.30

-0.22

-

-0.26

-0.47

-

-

-

-

-

-

-

-

-

-

-

Shares used in computing net loss per share of common stock, basic (in shares)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

45,312

45,286

44,577

44,406

44,343

43,873

43,715

43,469

43,333

43,190

-

41,462

37,262

-

-

-

-

-

-

-

-

-

-

-

Shares used in computing net loss per share of common stock, diluted see Note 14 (in shares)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

45,312

45,296

44,054

45,049

44,343

44,426

45,525

44,263

44,310

43,190

-

41,462

37,262

-

-

-

-

-

-

-

-

-

-

-

Net loss per share of common stock, basic and diluted (in dollars per share)

-0.20

-0.18

-0.16

-0.16

-0.17

-0.17

-0.21

-0.20

-0.23

-0.19

-0.28

-0.29

-0.34

-

-0.25

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.34

-

-0.38

-0.35

-0.36

-0.31

-0.30

-0.25

-0.30

-5.38

-5.41

Shares used in computing net loss per share of common stock, basic and diluted – See Note 12 (in shares)

80,057

79,584

79,461

78,902

78,788

70,857

60,004

51,841

50,930

50,440

46,365

45,379

45,348

-

45,319

-

-

-

-

-

-

-

-

-

-

-

-

-

37,133

-

22,632

20,627

19,607

19,803

19,458

19,374

10,742

668

653

Product [Member]
Revenue

274

1,533

116

55

126

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Contract and Other Collaboration [Member]
Revenue

112

-

-

-

139

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Collaboration Agreement Revenue [Member]
Revenue

-

-

492

886

-

-

177

351

274

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Contract and Other [Member]
Revenue

-

-

-

-

-

-

200

467

69

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-